次要终点包括IRC评估的总生存期(OS)和总缓解率(ORR)。

Secondary end points included overall survival (OS) and overall response rate (ORR) per IRC.

youdao

主要研究终点为总缓解率(ORR)，采用评价标准为RECIST 1.1。

The primary end point was overall response rate (ORR) per investigator assessment (RECIST 1.1).

youdao

替吉奥联合顺铂作为一种新的新辅助化疗方案，治疗胃癌总缓解率达76％，是目前为止进展期胃癌化疗方案中缓解率最高的方案。

S-1 combined with CDDP as a new neoadjuvant chemotherapy, is the most efficient therapy in advanced gastric cancer at present, it's CR can be over 76%.

youdao